Cyclerion Therapeutics Revenue 2018-2021 | CYCN

Cyclerion Therapeutics revenue from 2018 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Cyclerion Therapeutics Annual Revenue
(Millions of US $)
2020 $2
2019 $5
2018 $
2017 $
Cyclerion Therapeutics Quarterly Revenue
(Millions of US $)
2021-06-30 $3
2021-03-31 $0
2020-12-31 $0
2020-09-30 $0
2020-06-30 $1
2020-03-31 $1
2019-12-31 $1
2019-09-30 $1
2019-06-30 $2
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.116B $0.002B
Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. The company's product pipeline consists of Olinciguat, Praliciguat and IW-6463 which are in clinical stage. Cyclerion Therapeutics Inc. is based in Cambridge, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00